Categories



TheLibertyMill




The Phaserl






AvatarProducts



House Passes Bill Allowing Government to Microchip Citizens With “Mental Disabilities”

by Whitney Webb, Activist Post:

Six years ago, NBC Nightly News boldly predicted that all Americans would be fitted with RFID microchips by the year 2017. Though, at the time, NBC’s prediction seemed far-fetched, the House recently passed a bill that would bring a microchipped populace closer to reality before year’s end.

Last Thursday, the House passed HR 4919, also known as Kevin and Avonte’s Law, which would allow the US attorney general to award grants to law enforcement for the creation and operation of “locative tracking technology programs.” Though the program’s mission is to find “individuals with forms of dementia or children with developmental disabilities who have wandered from safe environments,” it provides no restriction on the tracking program’s inclusion of other individuals. The bill would also require the attorney general to work with the secretary of health and human services and unnamed health organizations to establish the “best practices” for the use of tracking devices.


Those in support of the legislation maintain that such programs could prevent tragedies where those with mental or cognitive disabilities wandered into dangerous circumstances. Yet, others have called these good intentions a “Trojan horse” for the expansion of a North American police state as the bill’s language could be very broadly interpreted.

Read More @ ActivistPost.com

Help us spread the ANTIDOTE to corporate propaganda.

Please follow SGT Report on Twitter & help share the message.

4 comments to House Passes Bill Allowing Government to Microchip Citizens With “Mental Disabilities”

  • F16hoser

    In other news; House passes bill saying All US Citizens are mental.

    • Steelerdude

      Exactly F16…the way they categorize people today, specially voting for trumph, we
      are all mental and should be chipped…

      • Steelerdude

        you know, this is a defining moment…this is the time we list the house reps, the senate, the congressmen that are just not going to do it for us to make America great again….so when you see an article like this, you need to research it a bit further,
        find out those who voted for this and those who didnt.

        WE MUST CLEAN UP THE SWAMP NOW!

  • rich

    So they have money for chips but not this?

    Analysts track a payer revolt against Sarepta’s controversial Duchenne drug $SRPT
    When the FDA’s Janet Woodcock pushed through a controversial approval for Sarepta’s Exondys 51 for Duchenne muscular dystrophy in September, she created a test case for payers who were essentially being asked to reimburse for an experimental drug.
    But instead of rolling with the situation and paying a price that starts at $300,000 or so a year, many of the payers are kicking back hard, according to a survey of payers conducted by Jefferies.
    Gena Wang, Jeffries
    “We conducted in depth due diligence on Exondys 51 launch with 4 private payers, 3 Medicaid experts, and 2 DMD KOLs with experience in administering Exondys 51,” noted Jefferies Gena Wang, who had been in the large contingent of analysts who had predicted a rejection for Sarepta. In addition we compiled a comprehensive list of published medical policies from 21 private payers (5 national & 15 regional MCOs; 1 PBM). Based on available data, 3/5 national and 8/15 regional managed care organizations (MCOs) have denied/restricted coverage for Exondys 51, in line with our expectation of pushback from private payers.”
    That pushback has cost Sarepta $SRPT plenty. The biotech has seen its share price fade back by about half since the approval more than two months ago as questions have continued to circulate about payers’ position on the drug.
    Anthem got the backlash rolling with its position that it will not cover an experimental drug, even though it’s been given an accelerated approval. And Humana followed up with restrictive rules that requires patients being able to walk so long as they are reimbursing for the drug. It’s clear from the Jefferies survey that a slight majority of payers don’t want to handle this like any other approved therapy for a rare and deadly disease.

    The kickback from payers is going to make it much harder for some of these families to get this drug, just when they felt that the biggest hurdle had already been cleared.
    https://endpts.com/analysts-track-a-payer-revolt-against-sareptas-controversial-duchenne-drug/

    They’re all scumbags.

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>